CeriBell (NASDAQ:CBLL) Sets New 12-Month Low – What’s Next?

Shares of CeriBell (NASDAQ:CBLL) hit a new 52-week low on Monday . The stock traded as low as $22.81 and last traded at $22.91, with a volume of 47261 shares trading hands. The stock had previously closed at $24.29.

Analysts Set New Price Targets

A number of research firms have recently issued reports on CBLL. JPMorgan Chase & Co. assumed coverage on CeriBell in a report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 target price on the stock. William Blair initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set an “outperform” rating for the company. Canaccord Genuity Group lifted their target price on shares of CeriBell from $31.00 to $33.00 and gave the company a “buy” rating in a report on Monday, December 9th. TD Cowen raised their price objective on shares of CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Finally, Canaccord Genuity Group started coverage on CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $30.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $32.60.

CeriBell Price Performance

The firm has a 50 day moving average of $27.27.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The company had revenue of $17.20 million for the quarter, compared to analysts’ expectations of $17.06 million. Analysts anticipate that CeriBell will post -2.46 earnings per share for the current year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.